DCLLSG

Completed Trials of the GCLLSG

CLL1
Prognostic factors and risk-adapted therapy in patients with early stage chronic lymphocytic leukemia
» more
CLL2
Multizentrische Phase II-Studie zur Evaluation von höher dosiertem Chlorambucil und von Fludarabin-Cyclophophamid bei forgeschrittener chronischer lymphatischer Leukämie
CLL2B
Treatment of patients with chronic lymphocytic leukemia with anti-CD20 antibody rituximab (IDEC-C2B8)
CLL2C
Treatment of patients with chronic lymphocytic leukemia using fludarabine and the anti-CD20 antibody Rituximab (IDEC-C2B8)
» more
CLL2D
Phase I/II-Studie zur Evaluation von Treosulfan bei fortgeschrittener chronischer lymphatischer Leukämie
CLL2E
Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: a phase I/II study of the German CLL Study Group
» more
CLL2F
Erhaltungstherapie mit Rituximab bei therapierefraktärer oder rezidivierter B-CLL
Multizentrische Phase-II-Studie
Diese Studie wurde nicht gestartet.
CLL2G
CHOP plus Rituximab (CHOP-R) in fludarabine refractory chronic lymphocytic leukemia (CLL) or CLL with autoimmune haemolytic anemia (AIHA) or Richter’s transformation (RT)
» more
CLL2H
Subcutaneous Campath-1H (Alemtuzumab; MabCampath®) in fludarabine-refractory CLL
» more
CLL2i
Consolidation therapy with Alemtuzumab (MabCampath ®) in patients with chronic lymphocytic leukemia who are in complete or partial 2nd remission after cytoreduction with fludarabine or fludarabine plus cyclophosphamide or fludarabine plus cyclophosphamide plus rituximab or bendamustine or bendamustine plus rituximab - a phase I/II study
» more
CLL2K
Treatment of relapsed / refractory chronic lymphocytic leukemia (CLL) with Bendamustin / Mitoxantrone (BM)
» more
CLL2L
Multicenter phase II trial of fludarabine and cyclophosphamide in combination with alemtuzumab for patients with relapsed or high risk chronic lymphocytic leukemia (FC-Cam)
» more
CLL2M
Multicentre phase II trial of Bendamustine in combination with rituximab for patients with previously untreated or relapsed chronic lymphocytic leukemia
» more
CLL2O
A prospective, multi-center phase II study of subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allogeneic stem-cell transplantation, in chronic lymphocytic leukemia which is associated with 17p deletion or is refractory to fludarabine
» more
CLL2P
A phase I/II safety and efficacy trial of a combination of bendamustine, rituximab and lenalidomide (BRL) with relapsed or refractory chronic lymphocytic leukemia (CLL) and a phase II efficacy trial for patients with previously untreated CLL
» more
CLL2s
A Phase I/II, Multi-centre Trial to Assess the Safety, Efficacy, and Pharmacokinetics of Eltrombopag, Administered to Thrombocytopenic Chronic Lymphocytic Leukemia Patients Prior to Alkylating Agents and/or Purine Analogue-based Therapy
» more
CLL2-BIG
A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 and ibrutinib (BIG) followed by GA101 and ibrutinib maintenance in CLL patients
» more
CLL2-BIO
A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by ofatumumab and ibrutinib followed by ibrutinib and ofatumumab maintenance in CLL patients
» more
CLL3
Pivotal Study for high dose therapy and autologous stem cell transplantation in early stages of CLL
» more
CLL3C
Campath-1H (Alemtuzumab) in Kombination mit Hochdosistherapie und autologer Stammzelltransplantation bei Patienten mit chronischer lymphatischer Leukämie
CLL3R
The value of autografting in patients with high-risk chronic lymphocytic leukemia. A randomized phase III intergroup trial.
This trial was prematurely terminated due to poor accrual.
» more
CLL3X
Pilot study on allogeneic stem cell transplantation following conditioning with fludarabine and an alkylating agent in patients with high-risk chronic lymphocytic leukemia
» more
CLL4
Fludarabine versus fludarabine plus cyclophosphamide in first line therapy of younger patients (up to 65 years) with advanced chronic lymphocytic leukemia (CLL)
» more
CLL4B
Consolidation therapy with CAMPATH-1H (alemtuzumab ) in patients ≤ 65 years with chronic lymphocytic leukemia who are in complete or partial remission after initial cytoreduction with fludarabine or fludarabine plus cyclophosphamide
» more
CLL5
Fludarabine versus chlorambucil in first line therapy of elderly patients (more than 65 years) with advanced chronic lymphocytic leukemia (CLL)
» more
CLL6
Treatment of advanced chronic lymphocytic leukemia (CLL) fludarabine, mitoxantrone and cyclophosphamide combination with or without G-CSF
CLL7
Randomized phase III trial comparing early treatment with fludarabine/cyclophosphamide + rituximab versus deferred treatment in untreated Binet stage A patients with high risk of progression
CLL7 protocol of the GCLLSG and FCGCLL
» more
CLL8
Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus chemotherapy with Fludarabine and Cyclophosphamide (FC) alone in patients with previously untreated chronic lymphocytic leukaemia
CLL-8 / ML17102 Protocol of the German CLL Study Group (GCLLSG)
» more
CLL9
Darbepoetin alfa in patients with chronic lymphocytic leukamia and comorbidity
» more
CLL10
Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic leukaemia
» more
CLL11
An open-label, multi-center, three arm randomized, phase III study to compare the efficacy and safety of RO5072759 + chlorambucil (GClb), rituximab + chlorambucil (RClb) or chlorambucil (Clb) alone in previously untreated CLL patients with comorbidities
» more
LGL1
First line therapy with methotrexate (MTX) and second line therapy with fludarabine of patients with T-cell large granular lymphocyte leukemia (T-LGL)
» more
PLL1
Phase-II-trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab in patients with B-PLL
» more
T-PLL1
Fludarabine, Mitoxantrone and Cyclophosphamide (FMC) in T-CLL and T-PLL followed by Alemtuzumab as consolidation
» more
T-PLL2
Phase II Trial of Combined Immunochemotherapy with Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients with Previously Treated or Untreated T-Prolymphocytic Leukemia
» more